Compare Medidata alternatives for EDC and clinical trial software: lighter, faster options with eConsent, ePRO, and 21 CFR Part 11–aligned controls.
21 CFR Part 11 aligned · HIPAA-aligned security · No credit card required
Medidata is a mature enterprise clinical trial platform, and for the right program that scale can be valuable. Large global trials, complex sponsor organizations, established data-management teams, and portfolios that already depend on Medidata workflows may benefit from the breadth of the ecosystem. A fair comparison should start there: the question is not whether enterprise EDC is good or bad, but whether it fits the study you are actually running. Many early-phase, small biotech, academic, and mid-size teams have a different set of constraints. They may need a study live quickly, have a small internal team, want integrated eConsent or ePRO without a separate project, and need pricing that matches a smaller cohort or shorter trial. In that situation, the overhead that supports enterprise programs can become a source of delay and coordination work. A useful Medidata alternatives evaluation should therefore separate enterprise capability from operational fit. If your trial needs the full enterprise stack, Medidata may remain appropriate. If your trial needs a focused EDC with consent, patient-reported data, safety forms, audit trails, and exports, a lighter system may be easier to implement and govern.
Vendor comparisons often start with feature grids, but feature parity does not always predict study success. A platform can check every box and still be difficult for a small team to deploy. For early-phase and mid-size studies, the practical questions are usually more specific: how long will study build take, who owns amendments, how are sites trained, how does eConsent connect to EDC, how is ePRO scheduled, and what documentation is available for sponsor validation? Capture is positioned for teams that want those core workflows in one platform. The evaluation should look at implementation path, study build flexibility, audit trails, role-based access, exports, support model, and whether the pricing structure fits the trial. It should also consider the cost of operating multiple systems if consent, EDC, and ePRO are purchased separately. This kind of comparison is more useful than asking which product has the longest feature list. A lean trial may benefit more from a system that is quick to configure, easy for sites to use, and clear for monitors to review. A large enterprise trial may justify a broader stack. The right answer depends on the work the system has to support.
Capture is not trying to replace every enterprise scenario. It is designed for teams that need clinical-trial-grade data capture without the implementation weight of a large platform. That includes Phase 1 and Phase 2 studies, small biotech programs, investigator-initiated trials, academic research, decentralized or hybrid studies, and focused studies that need EDC plus eConsent or ePRO in one place. The platform combines EDC, eConsent, ePRO, safety forms, queries, audit trails, role-based access, and exports. Study teams can configure forms and participant workflows around the protocol while keeping the clinical dataset governed. For regulated studies, Enterprise documentation can support sponsor validation and user acceptance testing, while the sponsor remains responsible for validating its own use of the system. For buyers comparing Medidata alternatives, Capture is strongest when the goal is faster launch, fewer vendors, simpler site experience, and a dataset that remains traceable from consent through export. It is worth evaluating when the trial does not need a broad enterprise suite but still needs disciplined clinical data governance.
Overview
Teams evaluating Medidata often look for alternatives that offer faster implementation, simpler pricing, and integrated eConsent and ePRO without enterprise-scale complexity. This page is for sponsors and CROs actively comparing EDC vendors or looking for a lighter, faster option for early-phase and mid-size trials. Capture is one alternative: a single platform for EDC, eConsent, ePRO, and safety with 21 CFR Part 11–aligned controls and HIPAA-aligned security, built for speed and flexibility without enterprise overhead.
Medidata is widely used for large, global Phase 3 trials. Many early-phase and small-to-mid-size teams find that implementation timelines, pricing models, and feature scope are geared toward enterprise programs. If you need rapid go-live, integrated eConsent and ePRO, and 21 CFR Part 11–aligned controls without long implementation or per-seat complexity, evaluating alternatives is common. Transparent comparison criteria include implementation speed, pricing fit, eConsent/ePRO integration, and support for sponsor validation.
FAQ
Explore the platform with a free sandbox. No sales call required.
Compare options